Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 344

Sort by

Sort Order Select

Journal Articles

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Blood (2024) 144 (7): 771–783.

https://doi.org/10.1182/blood.2024024299

Published: 2024

Includes: Supplemental data

Journal Articles

Targeting HUWE1 in Multiple Myeloma Leads to Impaired Replicative Stress Response and Enhanced Sensitivity to Bortezomib

Jonathan J Morgan, Bryony G Kennedy, Rich Williams, Ken I Mills, Lisa J Crawford

Blood (2023) 142 (Supplement 1): 2774.

https://doi.org/10.1182/blood-2023-185913

Published: 2023

Journal Articles

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

Beth Gordon, Lindsay Fogel, Gaurav Varma, Mateo Mejia Saldarriaga, Jaeil Ahn, Adolfo Aleman, Jessica Caro, Xiaoyi Chen, Jorge Monge, Harsh Parmar, David Kaminetzky, Tibor Moskovits, David S. Siegel, Gareth J. Morgan, Ruben Niesvizky, Noa Biran, Faith E. Davies

Blood (2023) 142 (Supplement 1): 4741.

https://doi.org/10.1182/blood-2023-181304

Published: 2023

Journal Articles

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Molly Reed, David Allan Cairns, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Annamaria Brioli, Matthew W. Jenner, Martin F. Kaiser, Catherine Olivier, Roger Owen, Kevin Boyd, Gordon Cook, Gareth J. Morgan, Graham Jackson, Mark Drayson, John R Jones

Blood (2023) 142 (Supplement 1): 3366.

https://doi.org/10.1182/blood-2023-181939

Published: 2023

Journal Articles

Whole-Genome Sequencing Identifies Structural Variation As a Key Driver of Disease Relapse and Aggressive Clinical Behavior in Multiple Myeloma

Marc Braunstein, Patrick Blaney, Gareth J. Morgan

Blood (2023) 142 (Supplement 1): 2773.

https://doi.org/10.1182/blood-2023-191008

Published: 2023

Journal Articles

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Marios Papadimitriou, Marilena Tauro, Bachisio Ziccheddu, Alexandra Maria Poos, Abdessamad Youssfi Alaoui, Mark B Meads, Kylee H Maclachlan, Saad Z Usmani, Marc S. Raab, Gareth J. Morgan, Niels Weinhold, Kenneth H. Shain, Ola Landgren, Francesco Maura

Blood (2023) 142 (Supplement 1): 639.

https://doi.org/10.1182/blood-2023-184784

Published: 2023

Journal Articles

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 874.

https://doi.org/10.1182/blood-2023-186802

Published: 2023

Journal Articles

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Blood (2023) 142 (Supplement 1): 3370.

https://doi.org/10.1182/blood-2023-187891

Published: 2023

Journal Articles

Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Nathan Beals, Craig Ramirez, Andy Hauser, Faith E. Davies, Dafna Bar-Sagi, Gareth J. Morgan

Blood (2023) 142 (Supplement 1): 54.

https://doi.org/10.1182/blood-2023-186114

Published: 2023

Journal Articles

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

Benjamin Diamond, Dickran Kazandjian, Marios Papadimitriou, Bachisio Ziccheddu, Patrick Blaney, Monika Chojnacka, Michael Durante, Elizabeth Hill, Romanos Sklavenitis-Pistofidis, Kylee H Maclachlan, Ryan M. Young, Saad Z Usmani, Faith E. Davies, Gad Getz, Irene M. Ghobrial, Gareth J. Morgan, Francesco Maura, Ola Landgren

Blood (2023) 142 (Supplement 1): 757.

https://doi.org/10.1182/blood-2023-181817

Published: 2023

Journal Articles

The Cellular Impact, Immediate Targets and Mechanism of Action of NSD2 in t(4;14) Multiple Myeloma

Yubao Wang, Sanxiong Liu, Hussein Ghamlouch, Eileen Boyle, Faith E. Davies, Gareth J. Morgan

Blood (2023) 142 (Supplement 1): 1402.

https://doi.org/10.1182/blood-2023-189012

Published: 2023

Journal Articles

Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development

Hussein Ghamlouch, Dylan Gagler, Patrick Blaney, Eileen Boyle, Yubao Wang, Liming Hou, Ola Landgren, Francesco Maura, Aristotelis Tsirigos, Gareth J. Morgan, Faith E. Davies

Blood (2023) 142 (Supplement 1): 332.

https://doi.org/10.1182/blood-2023-182968

Published: 2023

Journal Articles

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Francesco Maura, Marcella Kaddoura, Alexandra Maria Poos, Anthony Cirrincione, Benjamin Diamond, Kylee H Maclachlan, Bachisio Ziccheddu, Elias K. Mai, Hartmut Goldschmidt, Katja Weisel, Roland Fenk, Gareth J. Morgan, Saad Z Usmani, Ola Landgren, Marc S. Raab, Niels Weinhold

Blood (2023) 142 (Supplement 1): 638.

https://doi.org/10.1182/blood-2023-182267

Published: 2023

Journal Articles

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Blood (2023) 142 (Supplement 1): 1401.

https://doi.org/10.1182/blood-2023-190473

Published: 2023

Journal Articles

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Blood (2023) 142 (Supplement 1): 3764.

https://doi.org/10.1182/blood-2023-190882

Published: 2023

Journal Articles

Young and Distinct: Clinical Characteristics and Outcomes of Patients 50 or Younger with Multiple Myeloma

Andrea Tufano-Sugarman, Shahidul Islam, Faith E. Davies, Gareth J. Morgan, David Kaminetzky, Marc Braunstein

Blood (2023) 142 (Supplement 1): 6684.

https://doi.org/10.1182/blood-2023-182954

Published: 2023

Journal Articles

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Aikaterini Panopoulou, David A. Cairns, Amy Holroyd, Isabel Nichols, Nikita Cray, Charlotte Pawlyn, Gordon Cook, Mark Drayson, Kevin Boyd, Faith E. Davies, Matthew Jenner, Gareth J. Morgan, Roger Owen, Richard Houlston, Graham Jackson, Martin F. Kaiser

Blood (2023) 141 (14): 1666–1674.

https://doi.org/10.1182/blood.2022018339

Published: 2023

Includes: Supplemental data

Journal Articles

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

Charlotte Pawlyn, Tom Menzies, Faith E Davies, Ruth M. de Tute, Rowena Henderson, Gordon Cook, Matthew W Jenner, John R Jones, Martin F. Kaiser, Mark T Drayson, Roger G Owen, David Cairns, Gareth J. Morgan, Graham Jackson

Blood (2022) 140 (Supplement 1): 1371–1372.

https://doi.org/10.1182/blood-2022-165376

Published: 2022

Journal Articles

The Frequency of Alternative Splicing in Multiple Myeloma Is Determined By the Non-Homologous End Joining Pathway

Enze Liu, Nathan Becker, Parvathi Sudha, Chuanpeng Dong, Yunlong Liu, Jonathan J Keats, Gareth J. Morgan, Brian A. Walker

Blood (2022) 140 (Supplement 1): 4259–4260.

https://doi.org/10.1182/blood-2022-167322

Published: 2022

Journal Articles

Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial

John R Jones, David Cairns, Tom Menzies, Charlotte Pawlyn, Faith E. Davies, Rachel Sigsworth, Matthew W Jenner, Martin F. Kaiser, Rebecca Mottram, Mark T Drayson, Walter Martin Gregory, Roger G Owen, Kevin Boyd, Gordon Cook, Graham Jackson, Gareth J. Morgan

Blood (2022) 140 (Supplement 1): 1823–1825.

https://doi.org/10.1182/blood-2022-168723

Published: 2022

NARROW

The biological and clinical impact of deletions before and after large chromosomal gains in multiple myeloma

Targeting HUWE1 in Multiple Myeloma Leads to Impaired Replicative Stress Response and Enhanced Sensitivity to Bortezomib

Teclistamab Demonstrates Clinical Activity in Real-World Patients Ineligible for the Pivotal Majestec-1 Trial

The Impact of Epstein-Barr Virus Infection on Second Cancer Development in Newly Diagnosed Myeloma Patients Treated with Lenalidomide in the UK NCRI Myeloma XI Trial

Whole-Genome Sequencing Identifies Structural Variation As a Key Driver of Disease Relapse and Aggressive Clinical Behavior in Multiple Myeloma

Genomic and Transcriptomic Landscape of Hyper-Apobec Multiple Myeloma

Revealing Novel Mechanisms Underlying Inactivation of Tumor Suppressor Genes on Duplicated Chromosomes in Multiple Myeloma

Comprehensive Genomic Characterization of Response and Resistance to Daratumumab-Based Quadruplet Induction in Newly Diagnosed Multiple Myeloma Patients

Macropinocytosis As a Means of Selectively Targeting RAS-Mutant Multiple Myeloma

Genomic Profiling to Interpret the Outcomes of Early Intervention for High-Risk Smoldering Myeloma

The Cellular Impact, Immediate Targets and Mechanism of Action of NSD2 in t(4;14) Multiple Myeloma

Single Cell Analysis of Bone Marrow Stromal Cells Shows That a Pro-Inflammatory and Stress Response Together with Polarized Differentiation of Stromal Elements Characterize the Bone Marrow Microenvironment during Multiple Myeloma Development

The Temporal Evolution of Chromosome 1q Gain and Hyperdiploidy and Its Impact on Clinical Outcomes in Multiple Myeloma

Somatic Hypermutation in Enhancer Regions Shapes Non-Coding Myeloma Genome, Generating DNA Breaks and Driving Etiology through Mutation and Structural Variation

Whole-Genome Sequencing Reveals Distinct Mutational Signatures in Multiple Myeloma Patients with African Ancestry Compared with Those of Non-African Ancestry

Young and Distinct: Clinical Characteristics and Outcomes of Patients 50 or Younger with Multiple Myeloma

Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trial

Defining the Optimal Duration of Lenalidomide Maintenance after Autologous Stem Cell Transplant - Data from the Myeloma XI Trial

The Frequency of Alternative Splicing in Multiple Myeloma Is Determined By the Non-Homologous End Joining Pathway

Second Primary Malignancy Incidence in Patients Receiving Lenalidomide at Induction and Maintenance; Long-Term Follow up of 4358 Patients Enrolled to the Myeloma XI Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only